Gastroenterology pay hit $530,000 in 2025, according to Medscape’s Physician Compensation Report published April 11. The report, which surveyed 5,916 physicians across more than 29 specialties from Sept. 5 to Dec. 17, found that orthopedic surgeons are pulling in $611,000 a year while pediatricians take home less than half that at $266,000.
Author: Abhay Panchal
As GI procedures increasingly rely on anesthesia services, ASCs and gastroenterologists are exploring ways to capture a share of anesthesia revenue—but most of these arrangements sit on legally fragile ground. Nearly all models, whether service agreements, joint ventures, or employment structures, involve physicians benefiting from referrals they control—placing them squarely under scrutiny of federal and state anti-kickback and fee-splitting laws.
Gastroenterology ASCs are seeing rising procedural demand, yet margins continue to erode—not because of volume, but because of missed strategic levers. Key opportunities lie in areas many practices underutilize: payer strategy, employer contracting, operational efficiency, and screening expansion. In-network positioning is increasingly critical as independent dispute resolution (IDR) becomes a volume driver, while direct-to-employer contracting offers a largely untapped path to capture predictable, bundled revenue. At the same time, internal inefficiencies—device variation, poor scheduling, and underutilized block time—quietly inflate costs without improving throughput. The biggest growth lever, however, sits outside the system: millions of unscreened patients following updated colorectal cancer…
Early Phase 2 data from the SKYLINE trial suggest SPY001, a next-generation anti-α4β7 therapy for ulcerative colitis, could match existing biologics in efficacy while significantly improving dosing convenience through an extended half-life. Beyond clinical remission and endoscopic improvement, the real innovation lies in design—quarterly or even biannual subcutaneous dosing via autoinjector could reduce treatment burden and improve adherence compared to current therapies. The platform trial structure also points toward a broader strategy: combining gut-selective agents with cytokine-targeting therapies to enhance outcomes. As the IBD treatment landscape becomes increasingly crowded, differentiation is shifting from pure efficacy to a combination of durability,…
Iron deficiency anemia (IDA) is a complication often found in patients with gastrointestinal (GI) disorders. Despite this connection, the identification and management of IDA in patients with GI conditions remains inconsistent and inadequate. This Special Report reviews key aspects of recognizing, diagnosing, and managing IDA in patients with GI disorders with a focus on the utility of parenteral/IV iron for restoring iron stores often responsible for IDA development.
GLP-1 receptor agonists significantly increase the risk of retained gastric contents during upper endoscopy, with nearly 1 in 4 patients affected—and up to 50% in some settings without dietary prep. What’s changing is not just risk awareness, but protocol thinking. While early guidance pushed for holding these medications, emerging data suggest a simpler intervention—a clear liquid diet the day before the procedure—may mitigate much of the risk without interrupting therapy. At the same time, the absence of increased aspiration events reinforces that the clinical consequences may be more nuanced than initially feared. This is creating tension between guidelines and real-world…
Gastroenterology is rapidly becoming a focal point for innovation, with AI, robotics, and digital workflows transforming how diseases are detected, managed, and treated. From improved adenoma detection to AI-driven care pathways, the specialty is moving toward a more precise and data-driven model of care. But the bottlenecks are no longer technological—they’re operational. Limited OR capacity, payer restrictions, and workforce constraints are slowing adoption and limiting access, even as demand for GI services continues to rise. At the same time, emerging evidence suggests overreliance on AI could impact core clinical skills, reinforcing the need for balanced integration.
A new study evaluating 21 large language models found a consistent pattern: while AI can arrive at the correct diagnosis when given complete information, it struggles with the core of clinical medicine—reasoning through uncertainty. Across real-world clinical scenarios, models failed to generate appropriate differential diagnoses more than 80% of the time, highlighting a critical gap in early-stage decision-making. The issue isn’t accuracy at the endpoint—it’s the inability to navigate the stepwise diagnostic process, where incomplete information, judgment, and prioritization define care. The takeaway for healthcare is becoming clearer. AI is improving incrementally and can support tasks like data synthesis and…
A new MGMA report shows that regulatory burden has reached near-universal levels, with 95% of practices reporting increased strain—driven largely by Medicare Advantage requirements, prior authorizations, and audits. What stands out is how deeply administrative work is reshaping clinical operations. Many practices now employ multiple full-time staff per physician just to manage approvals, denials, and reporting requirements. As Medicare Advantage penetration grows, so does the operational friction—raising questions about long-term sustainability and whether some practices may opt out altogether. The downstream impact is no longer theoretical. Rising administrative load is directly contributing to physician burnout, reduced patient access, and shorter…
Blood-based ctDNA tests are gaining attention as a non-invasive alternative for colorectal cancer screening, offering high specificity and reasonable accuracy for detecting established cancers. However, a large meta-analysis shows their biggest limitation remains unchanged: poor detection of precancerous lesions, the very targets that enable true cancer prevention. While next-generation methylation assays are improving cancer detection rates, sensitivity for advanced precancerous lesions remains strikingly low. This creates a fundamental gap—ctDNA can help identify cancer once it is present, but lacks the ability to reliably intercept the disease earlier in its progression. In real-world screening populations, this also translates into low positive…